FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4239307613> ?p ?o ?g. }

• W4239307613 abstract "Abstract Background: This study aims to optimize the therapeutic regimen for refractory obstructive meibomian gland dysfunction (o-MGD) patients by combining intraductal meibomian gland probing (MGP) and intense pulsed light (IPL) to enhance their positive effects and reduce their limitations. Methods: This randomized, assessor blind study includes 45 patients (90 eyes) with refractory o-MGD who were divided into 3 groups via allocation concealment: IPL (group I, received an IPL treatment course: 3 times at 3-week intervals), MGP (group II, received MGP one time), and combined MGP-IPL (group III, MGP first followed by an IPL treatment course). Standard Patient Evaluation of Eye Dryness score (SPEED), tear break-up time (TBUT), corneal fluorescein staining (CFS), meibum grade, and lid margin finding results were assessed at baseline, 3 weeks after final treatment for groups I and III, 3 and 12 weeks after MGP for group II. Six months after final treatment, the SPEED and willingness to receive any treatment again were also collected for all groups. Paired Wilcoxon, Mann-Whitney U with Bonferroni correction, and Kruskal-Wallis tests were used for data analysis. Results: For all 3 groups, all previously mentioned indexes improved significantly following treatment (P＜0.01). MGP-IPL was better than IPL and MGP in terms of post-treatment SPEED, TBUT, meibum grade, and lid telangiectasia (P＜0.05/3). Furthermore, the MGP-IPL was better than IPL in terms of lid tenderness and better than MGP in terms of orifice abnormality (P＜ 0.05/3). Six months later, the SPEED for the MGP-IPL was also significantly lower than other groups (P＜0.05/3). Moreover, no patients in the MGP-IPL group expressed the need to be treated again compared to 35.7% or 20% of patients in the IPL or MGP groups, respectively. Conclusions: Compared with IPL or MGP alone, the combination MGP-IPL produced best results in relieving all signs and symptoms and helping patients attain long-lasting symptom relief. Trial registration: http://clinicaltrials.gov, ChiCTR1900021273 (retrospectively registered February 9, 2019)." @default.
• W4239307613 created "2022-05-12" @default.
• W4239307613 creator A5015433965 @default.
• W4239307613 creator A5015860750 @default.
• W4239307613 creator A5025374591 @default.
• W4239307613 creator A5075726970 @default.
• W4239307613 creator A5077923145 @default.
• W4239307613 creator A5079528837 @default.
• W4239307613 date "2019-10-07" @default.
• W4239307613 modified "2023-09-28" @default.
• W4239307613 title "Clinical Results of Intraductal Meibomian Gland Probing Combined with Intense Pulsed Light in Treating Patients with Refractory Obstructive Meibomian Gland Dysfunction: A Randomized Controlled Trial" @default.
• W4239307613 doi "https://doi.org/10.21203/rs.2.4294/v3" @default.
• W4239307613 hasPublicationYear "2019" @default.
• W4239307613 type Work @default.
• W4239307613 citedByCount "0" @default.
• W4239307613 crossrefType "posted-content" @default.
• W4239307613 hasAuthorship W4239307613A5015433965 @default.
• W4239307613 hasAuthorship W4239307613A5015860750 @default.
• W4239307613 hasAuthorship W4239307613A5025374591 @default.
• W4239307613 hasAuthorship W4239307613A5075726970 @default.
• W4239307613 hasAuthorship W4239307613A5077923145 @default.
• W4239307613 hasAuthorship W4239307613A5079528837 @default.
• W4239307613 hasBestOaLocation W42393076131 @default.
• W4239307613 hasConcept C118487528 @default.
• W4239307613 hasConcept C121332964 @default.
• W4239307613 hasConcept C126322002 @default.
• W4239307613 hasConcept C142424586 @default.
• W4239307613 hasConcept C16005928 @default.
• W4239307613 hasConcept C168563851 @default.
• W4239307613 hasConcept C2776714205 @default.
• W4239307613 hasConcept C2777165675 @default.
• W4239307613 hasConcept C2781302119 @default.
• W4239307613 hasConcept C71924100 @default.
• W4239307613 hasConcept C87355193 @default.
• W4239307613 hasConceptScore W4239307613C118487528 @default.
• W4239307613 hasConceptScore W4239307613C121332964 @default.
• W4239307613 hasConceptScore W4239307613C126322002 @default.
• W4239307613 hasConceptScore W4239307613C142424586 @default.
• W4239307613 hasConceptScore W4239307613C16005928 @default.
• W4239307613 hasConceptScore W4239307613C168563851 @default.
• W4239307613 hasConceptScore W4239307613C2776714205 @default.
• W4239307613 hasConceptScore W4239307613C2777165675 @default.
• W4239307613 hasConceptScore W4239307613C2781302119 @default.
• W4239307613 hasConceptScore W4239307613C71924100 @default.
• W4239307613 hasConceptScore W4239307613C87355193 @default.
• W4239307613 hasLocation W42393076131 @default.
• W4239307613 hasLocation W42393076132 @default.
• W4239307613 hasLocation W42393076133 @default.
• W4239307613 hasOpenAccess W4239307613 @default.
• W4239307613 hasPrimaryLocation W42393076131 @default.
• W4239307613 hasRelatedWork W2622079263 @default.
• W4239307613 hasRelatedWork W2800155498 @default.
• W4239307613 hasRelatedWork W2900045077 @default.
• W4239307613 hasRelatedWork W3010684284 @default.
• W4239307613 hasRelatedWork W3031876644 @default.
• W4239307613 hasRelatedWork W3134271791 @default.
• W4239307613 hasRelatedWork W3177163352 @default.
• W4239307613 hasRelatedWork W4229442654 @default.
• W4239307613 hasRelatedWork W4294433632 @default.
• W4239307613 hasRelatedWork W4313211561 @default.
• W4239307613 isParatext "false" @default.
• W4239307613 isRetracted "false" @default.
• W4239307613 workType "article" @default.